Total Payments
$205,943
2024 Payments
$12,682
Companies
7
Transactions
113
Medicare Patients
461
Medicare Billing
$78,508
Payment Breakdown by Category
Consulting$126,588 (61.5%)
Research$39,678 (19.3%)
Travel$38,115 (18.5%)
Food & Beverage$1,561 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $126,588 | 24 | 61.5% |
| Unspecified | $39,678 | 11 | 19.3% |
| Travel and Lodging | $38,115 | 46 | 18.5% |
| Food and Beverage | $1,561 | 32 | 0.8% |
Payments by Type
General
$166,264
102 transactions
Research
$39,678
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $71,842 | 85 | $0 (2024) |
| ModernaTX, Inc. | $51,513 | 3 | $0 (2023) |
| GlaxoSmithKline, LLC. | $28,992 | 9 | $0 (2024) |
| Novartis Pharma AG | $19,879 | 8 | $0 (2023) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $15,925 | 2 | $0 (2018) |
| Gilead Sciences Inc | $11,192 | 4 | $0 (2017) |
| Novo Nordisk AS | $6,600 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $12,682 | 7 | GlaxoSmithKline, LLC. ($8,850) |
| 2023 | $73,322 | 11 | ModernaTX, Inc. ($51,513) |
| 2022 | $2,725 | 2 | Novartis Pharma AG ($2,725) |
| 2021 | $3,157 | 2 | GlaxoSmithKline, LLC. ($1,882) |
| 2020 | $28,177 | 9 | GlaxoSmithKline, LLC. ($9,773) |
| 2019 | $41,614 | 33 | Merck Sharp & Dohme Corporation ($38,889) |
| 2018 | $10,281 | 13 | NOVARTIS PHARMACEUTICALS CORPORATION ($8,663) |
| 2017 | $33,984 | 36 | Merck Sharp & Dohme Corporation ($15,530) |
All Payment Transactions
113 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/12/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $8,850.00 | General |
| 06/12/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $3,022.50 | General |
| 06/12/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 06/05/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug) | Travel and Lodging | In-kind items and services | $411.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/05/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug) | Food and Beverage | In-kind items and services | $124.65 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/05/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug) | Food and Beverage | In-kind items and services | $64.20 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 06/05/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug) | Food and Beverage | In-kind items and services | $59.43 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/14/2023 | Novartis Pharma AG | COSENTYX (Biological) | — | Cash or cash equivalent | $1,462.50 | Research |
| Study: CAIN457M2301E1 • Category: DERMATOLOGY | ||||||
| 08/18/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $20,262.50 | General |
| 08/18/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,512.50 | General |
| 07/21/2023 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $370.95 | General |
| 06/29/2023 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $153.98 | General |
| 06/26/2023 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $208.73 | General |
| 05/23/2023 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $7,753.48 | General |
| 04/26/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $6,510.00 | General |
| 04/26/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 03/08/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $29,737.50 | General |
| 01/09/2023 | Novartis Pharma AG | COSENTYX (Biological) | — | Cash or cash equivalent | $5,200.00 | Research |
| Study: CAIN457M2301E1 • Category: DERMATOLOGY | ||||||
| 08/23/2022 | Novartis Pharma AG | COSENTYX (Biological) | — | Cash or cash equivalent | $1,090.00 | Research |
| Study: CAIN457M2301 & CAIN457M2302 • Category: DERMATOLOGY | ||||||
| 05/10/2022 | Novartis Pharma AG | COSENTYX (Biological) | — | Cash or cash equivalent | $1,635.00 | Research |
| Study: CAIN457M2301 & CAIN457M2302 • Category: DERMATOLOGY | ||||||
| 07/26/2021 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $1,275.00 | General |
| 06/16/2021 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,882.05 | General |
| 12/22/2020 | Novo Nordisk AS | — | — | Cash or cash equivalent | $4,800.00 | Research |
| Study: EX6018-4758 | ||||||
| 12/21/2020 | Novo Nordisk AS | — | — | Cash or cash equivalent | $1,800.00 | Research |
| Study: EX6018-4758 | ||||||
| 12/09/2020 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $998.80 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED EVENT DRIVEN TRIAL OF QUARTERLY SUBCUTANEOUS CANAKINUMAB IN THE PREVENTION OF RECURRENT CARDIOVASCULAR EVENTS AMONG STABLE POST MYOCARDIAL INFARCTION PATIENTS WITH ELEVATED HSCRP | NOVARTIS PHARMACEUTICALS CORPORATION | $15,925 | 2 |
| CAIN457M2301 & CAIN457M2302 | Novartis Pharma AG | $10,491 | 5 |
| CAIN457M2301E1 | Novartis Pharma AG | $6,663 | 2 |
| EX6018-4758 | Novo Nordisk AS | $6,600 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 68 | 92 | $36,881 | $10,808 |
| 2022 | 4 | 103 | 157 | $60,574 | $18,869 |
| 2021 | 5 | 122 | 193 | $66,428 | $21,216 |
| 2020 | 6 | 168 | 258 | $78,247 | $27,614 |
Total Patients
461
Total Services
700
Medicare Billing
$78,508
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 37 | 59 | $18,220 | $5,911 | 32.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 31 | 33 | $18,661 | $4,898 | 26.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 35 | 82 | $23,694 | $7,175 | 30.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 36 | 42 | $23,428 | $7,119 | 30.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 20 | 20 | $9,407 | $3,053 | 32.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 12 | 13 | $4,045 | $1,522 | 37.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 42 | 105 | $29,729 | $9,152 | 30.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 36 | 39 | $21,439 | $6,710 | 31.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 15 | 15 | $6,884 | $2,243 | 32.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 14 | 16 | $4,838 | $2,036 | 42.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 15 | 18 | $3,538 | $1,075 | 30.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 47 | 121 | $30,411 | $10,871 | 35.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 48 | 50 | $25,115 | $8,721 | 34.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 17 | 17 | $6,684 | $2,425 | 36.3% |
| 99358 | Prolonged patient service without direct patient contact first hour | Facility | 2020 | 21 | 22 | $5,995 | $2,151 | 35.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 21 | 31 | $5,577 | $1,903 | 34.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 14 | 17 | $4,465 | $1,545 | 34.6% |
About Dr. Abhijit Limaye, MD
Dr. Abhijit Limaye, MD is a Internal Medicine healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/29/2007. The National Provider Identifier (NPI) number assigned to this provider is 1205972239.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Abhijit Limaye, MD has received a total of $205,943 in payments from pharmaceutical and medical device companies, with $12,682 received in 2024. These payments were reported across 113 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($126,588).
As a Medicare-enrolled provider, Limaye has provided services to 461 Medicare beneficiaries, totaling 700 services with total Medicare billing of $78,508. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Infectious Disease, Infectious Disease
- Location San Francisco, CA
- Active Since 01/29/2007
- Last Updated 03/18/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1205972239
Products in Payments
- ILARIS (Biological) $15,925
- AIN457M_COSENTYX_DERMATOLOGY (Biological) $10,491
- COSENTYX (Biological) $9,388
- PREVYMIS (Drug) $3,977
- ZINPLAVA (Biological) $32.14
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in San Francisco
Dr. Fred Cohen, M.d, M.D
Internal Medicine — Payments: $1.6M
Internal Medicine $1.6M
John Teerlink, M.d, M.D
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Kenneth Binmoeller, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Dr. Hope Rugo, Md, MD
Internal Medicine — Payments: $881,117
Internal Medicine $881,117
Dr. Steven Harris, M.d, M.D
Internal Medicine — Payments: $806,637
Internal Medicine $806,637
Dr. Kenneth Colley, Md, MD
Internal Medicine — Payments: $732,736
Internal Medicine $732,736